After the GSK share price surges 16%, should I sell my shares?

After the GSK share price plunged to 10-year lows in late February, it has bounced back strongly. Should I hit, hold, or fold after this recent recovery?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

A GlaxoSmithKline scientist uses a microscope

Image: GlaxoSmithKline

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Early this year, I was closely following the share price of GlaxoSmithKline (LSE: GSK). Having peaked at 1,857p on 24 January 2020, the GSK share price collapsed. On Friday, 26 February 2021, the FTSE 100 stock closed below 1,191p. That’s a loss of over 666p — more than a third (35.9%) — in 13 months. Given that GSK is my largest personal shareholding, this was rather unpleasant for me.

The GSK share price drops to 10-year lows

With the GSK share price at lows not seen in a decade, I felt strongly that they were a bargain. On the very next day (Saturday, 26 February 2021), I said that GSK was among the cheapest of cheap shares in the Footsie. Back then, GSK shares traded on a price-to-earnings ratio of 10.6 and an earnings yield of 9.4%. The dividend yield of 6.7% a year was double that of the wider FTSE 100 index. To me, cheap as chips.

It seemed odd to me that, in the midst of a global pandemic, shares in the world’s #1 vaccine producer had fallen so steeply. Indeed, many of GSK’s Big Pharma rivals’ stocks had soared to new highs. Thus, I concluded that the market had mispriced this unloved and unwanted stock. Hence, instead of selling, I kept reinvesting my quarterly dividends into buying more GSK shares.

GSK shares get a shot in the arm

From February to April, I wrote several articles asking whether I should give up, dump my GSK shares, and move on. However, as a rational, long-term investor, it takes a lot to spook me into selling. Hence, I decided not to sell at such low prices. Furthermore, my wife then bought another chunk of GSK stock at roughly £1 above the late-February low. As I write on Tuesday afternoon, the GSK share price hovers around 1,418.8p. That’s 228p above February’s closing low — a gain of almost a sixth (16%) in 3½ months.

After a 16% recovery, should I sell?

Having added more than 4,000 additional GSK shares to our portfolio since February, is now finally the time to sell? I see two problems with selling our entire stake in this global giant. First, selling such a large shareholding would crystallise hefty capital gains at this improved GSK share price. Deducting the tax-free allowance of £12,300 for the 2021/22 tax year would leave further profits to be taxed at 20%. Ouch.

Second, I regard this FTSE 100 share as a key provider of dividend income for our portfolio. For the past five years (and for 2021/22, most likely), GSK has paid a steady cash dividend of 80p a share. This is paid quarterly and, based on the current GSK share price, equates to a dividend yield exceeding 5.6% a year. Staying within the safety of Footsie mega-stocks, it’s hard to replace such a high income stream without taking on greater levels of risk.

To sum up, my 35 years of investing have taught me this important lesson: act in haste, repent at leisure. In other words, I don’t rush into making snap decisions, because predicting the future is impossible. Then again, GSK has already confirmed that it plans to cut its chunky dividend in 2022. This will happen after it splits into a biopharma and a consumer-healthcare business. At this crucial juncture, I may change my mind about being a GSK shareholder. Until then, I might just sit tight!

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Cliffdarcy owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »